PF-06372865
Modify Date: 2024-02-28 10:13:30
PF-06372865 structure
|
Common Name | PF-06372865 | ||
|---|---|---|---|---|
| CAS Number | 1614245-70-3 | Molecular Weight | 440.493 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H21FN4O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-06372865PF-06372865 is a novel potent, α2/3 functionally selective GABAA receptor positive allosteric modulator; exhibits functional selectivity for receptors containing α2/3/5 subunits, with significant positive allosteric modulation (90-140%) but negligible activity (<20%) at GABAA receptors containing α1 subunits; demonstrates a robust increase in saccadic peak velocity, increases in beta frequency qEEG and a slight saturating increase in body sway in clinical trials. Epilepsy Phase 1 Clinical |
| Name | PF-06372865 |
|---|
| Description | PF-06372865 is a novel potent, α2/3 functionally selective GABAA receptor positive allosteric modulator; exhibits functional selectivity for receptors containing α2/3/5 subunits, with significant positive allosteric modulation (90-140%) but negligible activity (<20%) at GABAA receptors containing α1 subunits; demonstrates a robust increase in saccadic peak velocity, increases in beta frequency qEEG and a slight saturating increase in body sway in clinical trials. Epilepsy Phase 1 Clinical |
|---|---|
| References | References 1. Nickolls SA, et al. Br J Pharmacol. 2018 Feb;175(4):708-725. View Related Products by Target GABA Receptor Epilepsy |
| Molecular Formula | C22H21FN4O3S |
|---|---|
| Molecular Weight | 440.493 |